Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
DDI Strong CYP3A4 Inducer
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03082183
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT03077607
- Locations
- 🇲🇩
ARENSIA Exploratory Medicine Phase I Unit, PMSI Institute of Oncology, Chisinau, Moldova, Republic of
🇷🇺"BioEq" LLC, Saint-Petersburg, Russian Federation
🇷🇺I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin
- Conditions
- Interventions
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT03063580
- Locations
- 🇫🇷
Investigational Site Number 250001, Gieres, France
Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction
- Conditions
- Interventions
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT03048110
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 880
- Registration Number
- NCT03012529
- Locations
- 🇺🇸
Washington DC VA Medical Center, Washington, DC, Washington, District of Columbia, United States
🇺🇸Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States
🇺🇸Miami VA Healthcare System, Miami, FL, Miami, Florida, United States
To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 14
- Registration Number
- NCT03002493
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱University Medical Center Utrecht, Utrecht, Netherlands
Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan
- Conditions
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT02975440
A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT02959060
A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT02957448
Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 3900
- Registration Number
- NCT02901288
- Locations
- 🇨🇳
The Infectious Hospital of Hebi, Hebi, Henan, China
🇨🇳Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China
🇨🇳Anhui Chest Hospital, Hefei, Anhui, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.